Cooper Companies (NASDAQ:COO) Director Walter Rosebrough, Jr. Buys 7,000 Shares

The Cooper Companies, Inc. (NASDAQ:COO) Director Walter Rosebrough, Jr. acquired 7,000 shares of the business’s stock in a transaction that occurred on Friday, September 11th. The shares were bought at an average price of $54.11 per share, with a total value of $378,770.00. Following the completion of the transaction, the director directly owned 17,000 shares in the company, valued at approximately $919,870. The trade was a 70.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Cooper Companies Price Performance

Shares of NASDAQ:COO opened at $53.27 on Wednesday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.73 and a current ratio of 1.22. The business’s fifty day moving average price is $70.88 and its two-hundred day moving average price is $69.19. The stock has a market cap of $10.13 billion, a PE ratio of 18.18, a price-to-earnings-growth ratio of 2.21 and a beta of 0.82. The Cooper Companies, Inc. has a one year low of $51.01 and a one year high of $89.83.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings data on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.03. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%.The business had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.10 billion. During the same period in the prior year, the business earned $0.49 earnings per share. The business’s revenue was up .5% on a year-over-year basis. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. On average, analysts forecast that The Cooper Companies, Inc. will post 4.53 EPS for the current fiscal year.

Cooper Companies announced that its Board of Directors has approved a share repurchase program on Wednesday, September 9th that permits the company to buyback $3.00 billion in shares. This buyback authorization permits the medical device company to purchase up to 22.7% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s board of directors believes its stock is undervalued.

Institutional Trading of Cooper Companies

Several institutional investors have recently made changes to their positions in the stock. Sequoia Financial Advisors LLC increased its holdings in shares of Cooper Companies by 290.4% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 34,286 shares of the medical device company’s stock worth $2,459,000 after buying an additional 25,504 shares during the last quarter. Tidal Investments LLC raised its position in shares of Cooper Companies by 281.4% in the 2nd quarter. Tidal Investments LLC now owns 82,903 shares of the medical device company’s stock worth $5,945,000 after buying an additional 61,165 shares during the period. National Pension Service boosted its holdings in Cooper Companies by 9,314.0% in the second quarter. National Pension Service now owns 526,149 shares of the medical device company’s stock valued at $37,730,000 after acquiring an additional 520,560 shares during the last quarter. WINTON GROUP Ltd boosted its holdings in Cooper Companies by 379.0% in the second quarter. WINTON GROUP Ltd now owns 42,483 shares of the medical device company’s stock valued at $3,046,000 after acquiring an additional 33,613 shares during the last quarter. Finally, Engineers Gate Manager LP grew its position in Cooper Companies by 8,637.7% during the second quarter. Engineers Gate Manager LP now owns 249,897 shares of the medical device company’s stock valued at $17,920,000 after acquiring an additional 247,037 shares during the period. 24.39% of the stock is owned by hedge funds and other institutional investors.

More Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Three Cooper Companies directors reported approximately $1.33 million in combined stock purchases. Paul A. Keel bought 4,701 shares for roughly $250,000, Lawrence Kurzius purchased 10,000 shares for $539,100, and Walter M. Rosebrough Jr. acquired 10,000 shares across two transactions for approximately $541,640. The purchases may indicate that company insiders view the recent selloff as excessive. SEC insider purchase filing
• Positive Sentiment: An analysis titled “A Little More Compelling At This Price” suggests COO’s valuation has become more attractive following the decline, potentially supporting interest from value-oriented investors. Seeking Alpha analysis
• Neutral Sentiment: Rosen Law Firm announced an investigation into potential securities claims involving allegations that Cooper Companies may have issued materially misleading business information. The announcement does not establish wrongdoing, but it adds legal and headline risk for shareholders. Rosen Law Firm announcement
• Negative Sentiment: Cooper Companies reduced fiscal 2026 adjusted EPS guidance to $4.51–$4.55 from $4.58–$4.66 and cut revenue guidance to $4.23–$4.25 billion from $4.29–$4.32 billion. The revisions reflect weaker-than-expected contact-lens demand, particularly at CooperVision. Insider Monkey report
• Negative Sentiment: Reports indicated that third-quarter results included U.S. channel inventory destocking and other negative surprises, contributing to the sharp decline in COO shares. Investors are likely focused on how quickly distributors normalize inventories and whether underlying demand improves. HBSS report

Wall Street Analyst Weigh In

COO has been the subject of several recent analyst reports. Robert W. Baird set a $61.00 target price on shares of Cooper Companies and gave the stock a “neutral” rating in a research note on Thursday, September 10th. BNP Paribas Exane lowered their price objective on Cooper Companies from $95.00 to $92.00 and set an “outperform” rating for the company in a research report on Monday, June 8th. Mizuho set a $75.00 target price on Cooper Companies and gave the company an “outperform” rating in a research note on Thursday, September 10th. Wall Street Zen downgraded Cooper Companies from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Citigroup reissued a “neutral” rating and issued a $60.00 price target (down from $80.00) on shares of Cooper Companies in a research note on Thursday, September 10th. Five analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $71.47.

Cooper Companies Company Profile

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.